Significant Enhancements to Sequel System Enable >99% Accuracy for Single-Molecule Reads up to 15 kb; Throughput Increases by 2- to 4-Fold
Combined, the enhancements in the Sequel System 6.0 release improve the performance and affordability of Single Molecule, Real-Time (
- For amplicon and RNA sequencing projects, customers can generate up to 500,000 single-molecule reads with high fidelity (>99% single-molecule accuracy); and
- For whole genome sequencing projects, users can achieve up to 20 Gb per SMRT Cell with average read lengths up to 30 kb and high consensus accuracy (>99.999%).
Since SMRT Sequencing technology was first commercialized in 2011, Pacific Biosciences has increased the throughput per SMRT Cell by 2,000-fold. These ongoing throughput increases provide a significant cost savings for sequencing projects in the human, plant and animal markets, which allows researchers the opportunity to increase the size and scope of their projects.
“These enhancements represent the most significant improvement in terms of read length, throughput and accuracy that we have ever achieved in a single product release,” said
More information about the Sequel System is available at: https://www.pacb.com/products-and-services/sequel-system/ and more information about this latest release is available at: https://www.pacb.com/products-and-services/sequel-system/latest-system-release/
About Pacific Biosciences
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future availability, uses, accuracy, quality or performance of, or benefits of using, products or technologies, product improvements or enhancements, the suitability or utility of methods, products or technologies for particular applications, studies or projects, the expected costs or benefits of sequencing projects, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Source: Pacific Biosciences of California, Inc.